

## Kaiser Foundation Health Plan of Washington

# *Clinical Review Criteria* Cell-Free Fetal DNA Analysis

- Panorama
- MaterniT21<sup>™</sup>
- Harmony<sup>™</sup>
- Verifi™
- QNatal Advanced

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.** 

## Criteria

# Preferred Lab for Genetic Testing for Kaiser Permanente non-Medicare enrollees (for in-network coverage)

Prevention and Invitae/LabCorp Genetics is the preferred labs for genetic testing<sup>\*</sup>, when the test(s) is/are available at Prevention and LabCorp and medical necessity criteria are met.

Prevention test catalog can be found here: <u>Prevention Test Catalog</u> LabCorp test catalog can be found here: <u>LabCorp Test Catalog</u> Invitae test catalog can be found here: <u>Invitae Test Catalog</u>

\*Note: This does not affect processing of tumor or other pathology specimens as they are not performed by Invitae.

#### PPO/POS members may use non-preferred labs at the out of network cost share.

## Exceptions

For the genetic test(s) listed below, please use the lab specified:

- Cell Free Fetal DNA testing Any of the below labs can be used:
  - Ariosa Diagnostics, Inc. (81507)
  - o LabCorp (81420)
  - Quest-QNatal (81420)
  - Natera: Panorama (81420), Pamorama Twins (0060U)

#### **For Medicare Members**

Source	Policy
CMS Coverage Manuals	None
National Coverage Determinations (NCD)	None
Local Coverage Determinations (LCD)	Molecular Diagnostic Tests (L36256)
Local Coverage Article	None

#### For Non-Medicare Members

Kaiser Permanente will cover cell-free fetal DNA testing for trisomies without clinical review for pregnant women regardless of age when performed at Ariosa Diagnostics (CPT code 81507) or at Natera (CPT code 81420) or at Labcorp (CPT code 81420) or at Quest-QNatal (81420).

Prior Authorization will still be required for Non-Invasive Prenatal Testing (NIPT) at any other lab in advance of submitting a claim for payment. For patients who are tested for trisomies using cell-free fetal DNA, the sequential screen and nuchal translucency (NT) ultrasound (76813/76814) should no longer be routinely ordered without clinical indication.

The only codes that Kaiser Permanente will pay for Cell-Free Fetal DNA Analysis for Trisomies are 81420 and 81507.

Considered	not	medically	/ necessary	/:
------------	-----	-----------	-------------	----

Test Name	Criteria Used	Codes
Cell-Free Fetal DNA - Microdeletion Syndromes	A-0848: This service is not covered per MCG guidelines	CPT – 81331 not medically necessary when performed using cell-free fetal DNA, 81422
Cell-Free Fetal DNA - Monogenic Disorders	A-0849: This service is not covered per MCG guidelines	CPT – 81479
Cell-Free Fetal DNA - Sex Chromosome Disorders	There is insufficient evidence in the published medical literature to show that this service/therapy is as safe as standard services/therapies and/or will provide better long term outcomes than current standard services/therapies.	CPT – 81479

## If requesting review for these services, please send the following documentation:

• Last 6 months of clinical notes from requesting provider &/or specialist

\*MCG Manuals are proprietary and cannot be published and/or distributed. However, on an individual member basis, Kaiser Permanente can share a copy of the specific criteria document used to make a utilization management decision. If one of your patients is being reviewed using these criteria, you may request a copy of the criteria by calling the Kaiser Permanente Clinical Review staff at 1-800-289-1363.

The following information was used in the development of this document and is provided as background only. It is provided for historical purposes and does not necessarily reflect the most current published literature. When significant new articles are published that impact treatment option, Kaiser Permanente will review as needed. This information is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage determinations.

## Background

Fetal chromosomal abnormalities occur in approximately 1 in 160 live births. Most fetal chromosomal abnormalities are aneuploidies, defined as an abnormal number of chromosomes. The trisomy syndromes are aneuploidies involving 3 copies of 1 chromosome. The most important risk factor for trisomy syndromes is maternal age. The approximate risk of a trisomy 21 (T21; Down syndrome) –affected birth is 1 in 1100 at age 25 to 29. The risk of a fetus with T21 (at 16 weeks of gestation) is about 1 in 250 at age 35 and 1 in 75 at age 40.1

T21 is the most common chromosomal aneuploidy and provides the impetus for current maternal serum screening programs. Other trisomy syndromes include T18 (Edwards syndrome) and T13 (Patau syndrome), which are the next most common forms of fetal aneuploidy, although the percentage of cases surviving to birth is low and survival beyond birth is limited. The prevalence of these other aneuploidies is much lower than the prevalence of T21 and identifying them is not currently the main intent of prenatal screening programs. Also, the clinical implications of identifying T18 and 1T3 are unclear because survival beyond birth is limited for both conditions.

Standard aneuploidy screening involves combinations of maternal serum markers and fetal ultrasound done at various stages of pregnancy. The detection rate for various combinations of noninvasive testing ranges from 60% to 96% when the false-positive rate is set at 5%. When tests indicate a high risk of a trisomy syndrome, direct karyotyping of fetal tissue obtained by amniocentesis or chorionic villous sampling (CVS) is required to confirm that T21 or another trisomy is present. Both amniocentesis and CVS are invasive procedures and have an associated risk of miscarriage. A new screening strategy that reduces unnecessary amniocentesis and CVS procedures and increases detection of T21, T18, and T13 could improve outcomes. Confirmation of positive

noninvasive screening tests with amniocentesis or CVS is recommended; with more accurate tests, fewer women would receive positive screening results.

Commercial, noninvasive, sequencing-based testing of maternal serum for fetal trisomy syndromes is now available. The test technology involves detection of cell-free fetal DNA fragments present in the plasma of pregnant women. As early as 8 to 10 weeks of gestation, these fetal DNA fragments comprise 6% to 10% or more of the total cell-free fetal DNA in a maternal plasma sample. The tests are unable to provide a result if the fetal fraction is too low (ie, <4%). Fetal fraction can be affected by maternal and fetal characteristics. For example, fetal fraction was found to be lower at higher maternal weights and higher with increasing fetal crown-rump length.

## Medical Technology Assessment Committee (MTAC)

#### MaterniT21

### 08/20/2012: MTAC REVIEW

**Evidence Conclusion**: Kaiser concluded that there is insufficient evidence to determine whether the MaterniT21 prenatal test to detect Down syndrome is medically appropriate for any patient.

<u>Articles</u>: In March 2012, Kaiser review MaterniT21 for the detection of trisomy 21. No additional studies were identified since the Kaiser review. The following technology assessment was selected for review: Kaiser Permanente. Sequenom's MaterniT21 prenatal test to detect Down syndrome. March 2012. http://cl.kp.org/pkc/national/cpg/intc/materials/MaterniT21toDetectTrisomy21(G121107).pdf.

The use of MaterniT21 does not meet the Kaiser Permanente Medical Technology Assessment Criteria.

## References

- Advani HV, Barrett AN, Evans MI, Choolani M. Challenges in non-invasive prenatal screening for subchromosomal copy number variations using cell-free DNA. Prenatal Diagnosis 2017;37(11):1067-1075. DOI: 10.1002/pd.5161.
- Allyse M, et al. Non-invasive prenatal testing: a review of international implementation and challenges. International Journal of Women's Health 2015;7:113-126. DOI: 10.2147/IJWH.S67124.
- Badeau M, et al. Genomics-based non-invasive prenatal testing for detection of fetal chromosomal aneuploidy in pregnant women. Cochrane Database of Systematic Reviews 2017, Issue 11. Art. No.: CD011767. DOI: 10.1002/14651858.CD011767.pub2.
- Benn P, et al. Position Statement from the Chromosome Abnormality Screening Committee on Behalf of the Board of the International Society for Prenatal Diagnosis. [Internet] International Society for Prenatal Diagnosis. 2015 Feb Accessed at: https://www.ispdhome.org/. [accessed 2024 Oct 18]
- Benn P. Non-invasive prenatal testing using cell free DNA in maternal plasma: recent developments and future prospects. Journal of Clinical Medicine 2014;3(2):537-565. DOI: 10.3390/jcm3020537.
- Bevilacqua É, et al. Performance of a targeted cell-free DNA prenatal test for 22q11.2 deletion in a large clinical cohort. Ultrasound in Obstetrics & Gynecology 2021;58(4):597-602. DOI: 10.1002/uog.23699.
- Bianchi DW, et al. DNA sequencing versus standard prenatal aneuploidy screening. New England Journal of Medicine 2014;370(9):799-808. DOI: 10.1056/NEJMoa1311037.
- Centers for Medicare and Medicaid Services. "Hospital services excluded from payment under the hospital outpatient prospective payment system." 42 CFR 419.22 Washington, DC 2023 Jul [accessed 2024 Oct 18] Accessed at: https://www.ecfr.gov/.
- Centers for Medicare and Medicaid Services. "Requirements relating to basic benefits." 42 CFR 422.101 Washington, DC 2023 Jun 05 [accessed 2024 Oct 18] Accessed at: https://www.ecfr.gov/.
- Centers for Medicare and Medicaid Services. Medicare Benefit Policy Manual. Chapter 14 Medical Devices Rev. 198 [Internet] Centers for Medicare and Medicaid Services. 2014 Nov 06 Accessed at:
- https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/. [accessed 2024 Oct 18] Centers for Medicare and Medicaid Services. Medicare Benefit Policy Manual. Chapter 15 - Covered Medical and Other Health Services Rev. 12171 [Internet] Centers for Medicare and Medicaid Services. 2023 Aug 03 Accessed at: https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/. [accessed 2024 Oct 18]
- Centers for Medicare and Medicaid Services. Medicare Benefit Policy Manual. Chapter 16 General Exclusions From Coverage Rev. 198 [Internet] Centers for Medicare and Medicaid Services. 2014 Nov 06 Accessed at: https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/. [accessed 2024 Oct 18]
- Centers for Medicare and Medicaid Services. Medicare Benefit Policy Manual. Chapter 14 Medical Devices Rev. 198 [Internet] Centers for Medicare and Medicaid Services. 2014 Nov 06 Accessed at:

https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/. [accessed 2024 Oct 18] [ Context Link 1 ]

- Chitty LS, et al. Non-invasive prenatal diagnosis of achondroplasia and thanatophoric dysplasia: next-generation sequencing allows for a safer, more accurate, and comprehensive approach. Prenatal Diagnosis 2015;35(7):656-662. DOI: 10.1002/pd.4583.
- Chitty LS, Lo YM. Noninvasive prenatal screening for genetic diseases using massively parallel sequencing of maternal plasma DNA. Cold Spring Harbor Perspectives in Medicine 2015;5(9):a023085. DOI: 10.1101/cshperspect.a023085.
- Chiu RW. Noninvasive prenatal testing by maternal plasma DNA analysis: Current practice and future applications. Scandinavian Journal of Clinical and Laboratory Investigation. Supplementum 2014;74(244):48-53. DOI: 10.3109/00365513.2014.936681.
- Dar P, et al. Cell-free DNA screening for prenatal detection of 22q11.2 deletion syndrome. American Journal of Obstetrics and Gynecology 2022;Online. DOI: 10.1016/j.ajog.2022.01.002.
- Dashe JS. Aneuploidy screening in pregnancy. Obstetrics & Gynecology 2016;128(1):181-194. DOI: 10.1097/AOG.00000000001385.
- Deng C, Liu S. Factors affecting the fetal fraction in noninvasive prenatal screening: a review. Frontiers in Pediatrics 2022;10:812781. DOI: 10.3389/fped.2022.812781.
- Dondorp W, et al. Non-invasive prenatal testing for an uploidy and beyond: challenges of responsible innovation in prenatal screening. European Journal of Human Genetics 2015;23(11):1592. DOI: 10.1038/ejhg.2015.109.
- Drury S, et al. Implementing non-invasive prenatal diagnosis (NIPD) in a National Health Service laboratory; from dominant to recessive disorders. Advances in Experimental Medicine and Biology 2016;924:71-75. DOI: 10.1007/978-3-319-42044-8\_14.
- Dugoff L, Mennuti MT, McDonald-McGinn DM. The benefits and limitations of cell-free DNA screening for 22q11.2 deletion syndrome. Prenatal Diagnosis 2017;37(1):53-60. DOI: 10.1002/pd.4864.
- Dungan JS, et al. Noninvasive prenatal screening (NIPS) for fetal chromosome abnormalities in a general-risk population: An evidence-based clinical guideline of the American College of Medical Genetics and Genomics (ACMG). Genetics in Medicine 2022;Online. DOI: 10.1016/j.gim.2022.11.004. (Reaffirmed 2023 Jan)
- Ferres MA, Hui L, Bianchi DW. Antenatal noninvasive DNA testing: clinical experience and impact. American Journal of Perinatology 2014;31(7):577-582. DOI: 10.1055/s-0034-1371706.
- Goldwaser T, Klugman S. Cell-free DNA for the detection of fetal aneuploidy. Fertility and Sterility 2018;109(2):195-200. DOI: 10.1016/j.fertnstert.2017.12.019.
- Hanson B, Scotchman E, Chitty LS, Chandler NJ. Non-invasive prenatal diagnosis (NIPD): how analysis of cellfree DNA in maternal plasma has changed prenatal diagnosis for monogenic disorders. Clinical Science 2022;136(22):1615-1629. DOI: 10.1042/CS20210380.
- Hardy T. The role of prenatal diagnosis following preimplantation genetic testing for single-gene conditions: A historical overview of evolving technologies and clinical practice. Prenatal Diagnosis 2020;40(6):647-651. DOI: 10.1002/pd.5662. [ Context Link 1 ] View abstract...
- Harris S, Reed D, Vora NL. Screening for fetal chromosomal and subchromosomal disorders. Seminars in Fetal and Neonatal Medicine 2018;23(2):85-93. DOI: 10.1016/j.siny.2017.10.006.
- Health Quality Ontario. Noninvasive prenatal testing for trisomies 21, 18, and 13, sex chromosome aneuploidies, and microdeletions: A Health Technology Assessment. Ontario Health Technology Assessment Series 2019;19(4):1-166.
- Hill M, et al. Non-invasive prenatal diagnosis for cystic fibrosis: detection of patient preferences and cost analysis. Prenatal Diagnosis 2015;35(10):950-958. DOI: 10.1002/pd.4585. [ Context Link 1 ] View abstract...
- Hudecova I, Chiu RW. Non-invasive prenatal diagnosis of thalassemias using maternal plasma cell free DNA. Best Practice and Research. Clinical Obstetrics and Gynaecology 2017;39:63-73. DOI: 10.1016/j.bpobgyn.2016.10.016. [Context Link 1] View abstract...
- Hui L, Bianchi DW. Fetal fraction and noninvasive prenatal testing: What clinicians need to know. Prenatal Diagnosis 2020;40(2):155-163. DOI: 10.1002/pd.5620.
- Jenkins LA, Deans ZC, Lewis C, Allen S. Delivering an accredited non-invasive prenatal diagnosis service for monogenic disorders and recommendations for best practice. Prenatal Diagnosis 2018;38(1):44-51. DOI: 10.1002/pd.5197. [Context Link 1] View abstract...
- Larion S, Warsof SL, Romary L, Mlynarczyk M, Peleg D, Abuhamad AZ. Uptake of noninvasive prenatal testing at a large academic referral center. American Journal of Obstetrics and Gynecology 2014;211(6):651, e1e7. DOI: 10.1016/j.ajog.2014.06.038.

- Ma D, et al. Haplotype-based approach for noninvasive prenatal diagnosis of congenital adrenal hyperplasia by maternal plasma DNA sequencing. Gene 2014;544(2):252-258. DOI: 10.1016/j.gene.2014.04.055. [ Context Link 1 ] View abstract...
- Mackie FL, Hemming K, Allen S, Morris RK, Kilby MD. The accuracy of cell-free fetal DNA-based non-invasive prenatal testing in singleton pregnancies: a systematic review and bivariate meta-analysis. BJOG: An International Journal of Obstetrics and Gynaecology 2017;124(1):32-46. DOI: 10.1111/1471-0528.14050. [Context Link 1] View abstract...
- Mahdi Mortazavipour M, Mahdian R, Shahbazi S. The current applications of cell-free fetal DNA in prenatal diagnosis of single-gene diseases: A review. International Journal of Reproductive Biomedicine 2022;20(8):613-626. DOI: 10.18502/ijrm.v20i8.11751. [Context Link 1] View abstract...
- Medicare Coverage Database. [Internet] Centers for Medicare and Medicaid Services. Accessed at: https://www.cms.gov/medicare-coverage-database/search.aspx? Updated 2023 [accessed 2024 Oct 18]
- Mellis R, Chandler N, Chitty LS. Next-generation sequencing and the impact on prenatal diagnosis. Expert Review of Molecular Diagnostics 2018;18(8):689-699. DOI: 10.1080/14737159.2018.1493924.
- Minear MA, Alessi S, Allyse M, Michie M, Chandrasekharan S. Noninvasive prenatal genetic testing: current and emerging ethical, legal, and social issues. Annual Review of Genomics and Human Genetics 2015;16:369-398. DOI: 10.1146/annurev-genom-090314-050000.
- Mohan P, et al. Clinical experience with non-invasive prenatal screening for single-gene disorders. Ultrasound in Obstetrics & Gynecology 2022;59(1):33-39. DOI: 10.1002/uog.23756.
- Panorama. Non-invasive Prenatal Testing (NIPT) [Internet] Natera, Inc. Accessed at: https://www.natera.com/womens-health/panorama-nipt-prenatal-screening. Updated 2023 [accessed 2024 Oct 18]
- Parks M, et al. Non-invasive prenatal diagnosis of Duchenne and Becker muscular dystrophies by relative haplotype dosage. Prenatal Diagnosis 2016;36(4):312-320. DOI: 10.1002/pd.4781.
- Parks M, et al. Non-invasive prenatal diagnosis of spinal muscular atrophy by relative haplotype dosage. European Journal of Human Genetics 2017;25(4):416-422. DOI: 10.1038/ejhg.2016.195.
- Rabinowitz M, Savage M, Pettersen B, Sigurjonsson S, Hill M, Zimmermann B. Noninvasive cell-free DNA-based prenatal detection of microdeletions using single nucleotide polymorphism-targeted sequencing. Obstetrics & Gynecology 2014;123 Suppl 1:167S. DOI: 10.1097/01.AOG.0000447172.98639.e5.
- Rabinowitz T, Shomron N. Genome-wide noninvasive prenatal diagnosis of monogenic disorders: Current and future trends. Computational and Structural Biotechnology Journal 2020;18:2463-2470. DOI: 10.1016/j.csbj.2020.09.003.
- Rink BD, Norton ME. Screening for fetal aneuploidy. Seminars in Perinatology 2016;40(1):35-43. DOI: 10.1053/j.semperi.2015.11.006.
- Rose NC, et al. Screening for fetal chromosomal abnormalities. ACOG Practice Bulletin No. 226. Joint Guideline of the ACOG Obstetrics, Committee on Genetics and Society for Maternal-Fetal Medicine. Obstetrics and Gynecology 2020;136(4):e48-e69. DOI: 10.1097/AOG.000000000004084. (Reaffirmed 2022 Jul)
- Rose NC, et al. Systematic evidence-based review: The application of noninvasive prenatal screening using cellfree DNA in general-risk pregnancies. Genetics in Medicine 2022;24(7):1379-1391. DOI: 10.1016/j.gim.2022.03.019.
- Scotchman E, Chandler NJ, Mellis R, Chitty LS. Noninvasive prenatal diagnosis of single-gene diseases: the next frontier. Clinical Chemistry 2020;66(1):53-60. DOI: 10.1373/clinchem.2019.304238.
- Scotchman E, Shaw J, Paternoster B, Chandler N, Chitty LS. Non-invasive prenatal diagnosis and screening for monogenic disorders. European Journal of Obstetrics, Gynecology, and Reproductive Biology 2020;253:320-327. DOI: 10.1016/j.ejogrb.2020.08.001.
- Shafei N, Hakhamaneshi MS, Houshmand M, Gerayeshnejad S, Fathi F, Sharifzadeh S. Diagnostic value of nonnvasive prenatal screening of beta-thalassemia by cell free fetal DNA and fetal NRBC. Current Molecular Medicine 2019;19(2):105-111. DOI: 10.2174/1566524019666190226124135.
- Shaffer BL, Norton ME. Cell-free DNA screening for aneuploidy and microdeletion syndromes. Obstetrics and Gynecology Clinics of North America 2018;45(1):13-26. DOI: 10.1016/j.ogc.2017.10.001.
- Shaw J, Scotchman E, Chandler N, Chitty L. Non-invasive prenatal testing for an euploidy, copy number variants and single gene disorders. Reproduction 2020;160(5):A1-A11. DOI: 10.1530/REP-19-0591.
- Skotko BG, et al. Adherence of cell-free DNA noninvasive prenatal screens to ACMG recommendations. Genetics in Medicine 2019;21(10):2285-2292. DOI: 10.1038/s41436-019-0485-2.
- Skrzypek H, Hui L. Noninvasive prenatal testing for fetal aneuploidy and single gene disorders. Best Practice and Research. Clinical Obstetrics and Gynaecology 2017;42:26-38. DOI: 10.1016/j.bpobgyn.2017.02.007. [
- Society for Maternal-Fetal Medicine (SMFM) with the assistance. Norton ME, Biggio JR, Kuller JA, Blackwell SC. SMFM Consult Series #42: The role of ultrasound in women who undergo cell-free DNA screening. American Journal of Obstetrics and Gynecology 2017;216(3):B2-B7. DOI: 10.1016/j.ajog.2017.01.005.

- Srinivasan A, Bianchi DW, Huang H, Sehnert AJ, Rava RP. Noninvasive detection of fetal subchromosome abnormalities via deep sequencing of maternal plasma. American Journal of Human Genetics 2013;92(2):167-176. DOI: 10.1016/j.aihg.2012.12.006.
- The NIFTY Test. [Internet] NiftyTest. Accessed at: https://www.niftytest.com/. Updated 2022 [created 2014; accessed 2024 Oct 18]
- Van den Oever JM, et al. Noninvasive prenatal diagnosis of Huntington disease: detection of the paternally inherited expanded CAG repeat in maternal plasma. Prenatal Diagnosis 2015;35(10):945-949. DOI: 10.1002/pd.4593.
- Van den Veyver IB. Recent advances in prenatal genetic screening and testing. F1000Research 2016;5:2591. DOI: 10.12688/f1000research.9215.1.
- Varela-Lema L, Punal-Rioboo J, Ballini L, Emilia-Romagna R. Screening of Fetal Trisomies 21, 18 and 13 by Noninvasive Prenatal Testing. [Internet] EUnetHTA. 2018 Feb Accessed at: https://www.eunethta.eu/. [accessed 2024 Oct 18]
- Vora NL, O'Brien BM. Noninvasive prenatal testing for microdeletion syndromes and expanded trisomies: proceed with caution. Obstetrics & Gynecology 2014;123(5):1097-1099. DOI: 10.1097/AOG.0000000000237.
- Wou K, Levy B, Wapner RJ. Chromosomal Microarrays for the Prenatal Detection of Microdeletions and Microduplications. Clinics in Laboratory Medicine 2016;36(2):261-276. DOI: 10.1016/j.cll.2016.01.017.
- Xiang J, Peng Z. Applications of noninvasive prenatal testing for subchromosomal copy number variations using cell-free DNA. Clinics in Laboratory Medicine 2022;42(4):613-625. DOI: 10.1016/j.cll.2022.09.014.
- Xiong L, et al. Non-invasive prenatal testing for fetal inheritance of maternal ß-thalassaemia mutations using targeted sequencing and relative mutation dosage: a feasibility study. BJOG: An International Journal of Obstetrics and Gynaecology 2018;125(4):461-468. DOI: 10.1111/1471-0528.15045.
- Yaron Y, Jani J, Schmid M, Oepkes D. Current status of testing for microdeletion syndromes and rare autosomal trisomies using cell-rree DNA technology. Obstetrics & Gynecology 2015;126(5):1095-1099. DOI: 10.1097/AOG.00000000001091.
- Yatsenko SA, Peters DG, Saller DN, Chu T, Clemens M, Rajkovic A. Maternal cell-free DNA-based screening for fetal microdeletion and the importance of careful diagnostic follow-up. Genetics in Medicine 2015;17(10):836-838. DOI: 10.1038/gim.2014.197.
- Zaninovic L, Baskovic M, Jezek D, Katusic Bojanac A. Validity and utility of non-invasive prenatal testing for copy number variations and microdeletions: a systematic review. Journal of Clinical Medicine 2022;11(12):Online. DOI: 10.3390/jcm11123350.
- Zeevi DA, et al. Proof-of-principle rapid noninvasive prenatal diagnosis of autosomal recessive founder mutations. Journal of Clinical Investigation 2015;125(10):3757-3765. DOI: 10.1172/JCI79322.
- Zhang H, et al. Non-invasive prenatal testing for trisomies 21, 18 and 13: clinical experience from 146,958 pregnancies. Ultrasound in Obstetrics & Gynecology 2015;45(5):530-538. DOI: 10.1002/uog.14792.

# **Applicable Codes**

## Considered Medically Necessary when criteria in the applicable policy statements listed above are met:

CPT® Codes	Description
81420	Fetal chromosomal aneuploidy (eg, trisomy 21, monosomy X) genomic sequence analysis panel, circulating cell-free fetal DNA in maternal blood, must include analysis of chromosomes 13, 18, and 21
81507	Fetal aneuploidy (trisomy 21, 18, and 13) DNA sequence analysis of selected regions using maternal plasma, algorithm reported as a risk score for each trisomy

#### Considered Not Medically Necessary when performed using cell-free fetal DNA:

CPT®	Description
Codes	
81331	SNRPN/UBE3A (small nuclear ribonucleoprotein polypeptide N and ubiquitin protein ligase E3A)
	(eg, Prader-Willi syndrome and/or Angelman syndrome), methylation analysis
81403	Molecular Pathology Procedure Level 4
81422	Fetal chromosomal microdeletion(s) genomic sequence analysis (eg, DiGeorge syndrome, Cri-du-
	chat syndrome), circulating cell-free fetal DNA in maternal blood
81479	Unlisted molecular pathology procedure

\*Note: Codes may not be all-inclusive. Deleted codes and codes not in effect at the time of service may not be covered.

\*\*To verify authorization requirements for a specific code by plan type, please use the Pre-authorization Code Check.

CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions, and materials are copyrighted by Centers for Medicare Services (CMS).

Date Created	Date Reviewed	Date Last Revised
09/04/2012	09/04/2012 <sup>MDCRPC</sup> , 10/02/2012 <sup>MDCRPC</sup> , 02/05/2013 <sup>MDCRPC</sup> , 1, 03/01/2022 <sup>MPC</sup> 2/03/2013 <sup>MPC</sup> , 01/07/2014 <sup>MPC</sup> , 11/04/2014 <sup>MPC</sup> , 09/01/2015 <sup>MPC</sup> , 07/05/2016 <sup>MPC</sup> , 05/02/2017 <sup>MPC</sup> , 03/06/2018 <sup>MPC</sup> , 03/05/2019 <sup>MPC</sup> , 03/03/2020 <sup>MPC</sup> , 03/02/2021 <sup>MPC</sup> , 03/01/2022 <sup>MPC</sup> ,03/07/2023 <sup>MPC</sup> , 10/01/2024 <sup>MPC</sup>	06/13/2024

MDCRPC Medical Director Clinical Review and Policy Committee MPC Medical Policy Committee

Revision	Description
History	
09/08/2015	Revised LCD L34101
07/05/2016	Adopted GHC-0724
04/08/2020	Added temporary change for code 81507 due to COVID-19 pandemic
06/02/2020	Extended temporary change until September 15, 2020 for code 81507 due to COVID-19 pandemic
08/04/2020	Extended temporary change until November 1, 2020 for code 81507 due to COVID-19 pandemic
12/07/2020	Extended temporary change until February 15, 2021 for code 81507 due to COVID-19 pandemic
03/08/2021	Extended temporary change until May 15, 2021 for code 81507 due to COVID-19 pandemic
05/04/2021	Extended temporary change until June 15, 2021 for code 81507 due to COVID-19 pandemic
06/01/2021	Extended temporary change until August 15, 2021 for code 81507 due to COVID-19 pandemic
08/03/2021	MPC approved to permanently eliminate age restrictions on cell-free fetal DNA (NIPT) testing for trisomies for commercial members (81507 and 81420). Prior authorization is still required for this testing at labs other than Ariosa. Requires 60-day notice, effective date January 1, 2022. Extended temporary change until December 31, 2021 for code 81507 due to COVID-19 pandemic.
03/01/2022	Updated applicable codes.
08/16/2022	MCG* A-0847 was removed from the 26 <sup>th</sup> edition; removed from criteria
10/7/2022	Added labcorp as preferred vendor for Cell Free Fetal DNA testing. Noted Prevention as preferred lab for genetic testing.
04/24/2023	Added Quest-QNatal as a preferred vendor for Cell Free Fetal DNA testing.
05/03/2024	Updated list of preferred lab vendors
06/13/2024	Removed MCG* A-0850 (guideline was updated in the 28 <sup>th</sup> ed.); retained position of non- coverage.
10/18/2024	Updated references
12/06/2024	LabCorp acquired Invitae Genetics test. Criteria was updated to reflect acquisition, effective November 15, 2024